This story has been updated to provide comments from Trovagene's management made during a conference call with investors.

NEW YORK (GenomeWeb) – Trovagene reported after the close of the market on Thursday that its fourth quarter revenues rose 41 percent year over year.

The liquid biopsy MDx developer said its revenues rose to $79,000 for the three months ended Dec. 31, 2015, up from $56,000 in Q4 2014. However, the revenues significantly missed analysts' estimates of $100,000 for the quarter.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

This year's Breakthrough Prize winners include a pair that developed a therapy for spinal muscular atrophy.

The New York Times reports on how white supremacists misconstrue genetic research, concerning many geneticists.

Researchers find that people's genetics influence their success at university, but that it is not the only factor.

In Nature this week: approach to identify genetic variants that affect trait variability, application of read clouds to microbiome samples, and more.